{"entity":{"id":"nct06969430","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","aka":[],"tldr":"A phase 1/2 trial of Debio 1562M in acute myeloid leukaemia, run by Debiopharm International SA, now recruiting.","summary":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) is a phase 1/2 interventional study registered as NCT06969430 by Debiopharm International SA, with 154 participants planned, started 2025-05-30 and due to reach its primary completion in 2031-11. Interventions recorded: Debio 1562M.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06969430","url":"https://clinicaltrials.gov/study/NCT06969430"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["debiopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06969430","phase":"1/2","setting":"A Phase 1/2, First-in-human, Multicenter, Open-label Trial Evaluating the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","sponsor":"Debiopharm International SA","enrolled":154,"outcomes":[]},"route":"/trials/nct06969430/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"company":[{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/"}]}}